vs
Side-by-side financial comparison of Lument Finance Trust, Inc. (LFT) and Sunshine Biopharma Inc. (SBFM). Click either name above to swap in a different company.
Sunshine Biopharma Inc. is the larger business by last-quarter revenue ($8.6M vs $5.4M, roughly 1.6× Lument Finance Trust, Inc.). Sunshine Biopharma Inc. runs the higher net margin — -25.0% vs -144.5%, a 119.6% gap on every dollar of revenue. On growth, Sunshine Biopharma Inc. posted the faster year-over-year revenue change (-10.6% vs -42.6%). Over the past eight quarters, Sunshine Biopharma Inc.'s revenue compounded faster (6.6% CAGR vs -35.7%).
Lument Finance Trust, Inc. is a US-based real estate finance firm that primarily invests in, manages, and operates credit assets tied to multifamily residential and commercial real estate. Its core offerings include bridge loans, permanent financing solutions, and structured real estate debt products for property owners and operators across the United States.
Sunshine Biopharma Inc. is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing innovative therapies for oncology, neurodegenerative disorders and infectious diseases. It targets unmet medical needs across global markets, with a pipeline of targeted therapeutic candidates designed to improve patient treatment outcomes.
LFT vs SBFM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.4M | $8.6M |
| Net Profit | $-7.8M | $-2.1M |
| Gross Margin | — | 35.3% |
| Operating Margin | — | -20.9% |
| Net Margin | -144.5% | -25.0% |
| Revenue YoY | -42.6% | -10.6% |
| Net Profit YoY | -262.0% | 0.8% |
| EPS (diluted) | $-0.17 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.4M | $8.6M | ||
| Q3 25 | $5.1M | $9.4M | ||
| Q2 25 | $7.0M | $9.4M | ||
| Q1 25 | $7.7M | $8.9M | ||
| Q4 24 | $9.4M | $9.6M | ||
| Q3 24 | $9.5M | $8.4M | ||
| Q2 24 | $9.5M | $9.3M | ||
| Q1 24 | $13.0M | $7.5M |
| Q4 25 | $-7.8M | $-2.1M | ||
| Q3 25 | $1.8M | $-883.8K | ||
| Q2 25 | $3.7M | $-1.8M | ||
| Q1 25 | $-522.6K | $-1.2M | ||
| Q4 24 | $4.8M | $-2.2M | ||
| Q3 24 | $6.3M | $-1.2M | ||
| Q2 24 | $4.6M | $-494.3K | ||
| Q1 24 | $7.0M | $-1.3M |
| Q4 25 | — | 35.3% | ||
| Q3 25 | — | 32.6% | ||
| Q2 25 | — | 36.4% | ||
| Q1 25 | — | 30.7% | ||
| Q4 24 | — | 32.2% | ||
| Q3 24 | — | 34.0% | ||
| Q2 24 | — | 25.3% | ||
| Q1 24 | — | 31.2% |
| Q4 25 | — | -20.9% | ||
| Q3 25 | — | -11.5% | ||
| Q2 25 | — | -21.8% | ||
| Q1 25 | — | -14.6% | ||
| Q4 24 | — | -21.7% | ||
| Q3 24 | — | -13.1% | ||
| Q2 24 | — | -13.6% | ||
| Q1 24 | — | -17.9% |
| Q4 25 | -144.5% | -25.0% | ||
| Q3 25 | 36.5% | -9.4% | ||
| Q2 25 | 53.0% | -18.8% | ||
| Q1 25 | -6.8% | -13.3% | ||
| Q4 24 | 51.2% | -22.5% | ||
| Q3 24 | 66.2% | -14.2% | ||
| Q2 24 | 48.3% | -5.3% | ||
| Q1 24 | 53.7% | -17.0% |
| Q4 25 | $-0.17 | — | ||
| Q3 25 | $0.01 | $-0.54 | ||
| Q2 25 | $0.05 | $-0.82 | ||
| Q1 25 | $-0.03 | $-0.44 | ||
| Q4 24 | $0.06 | $49.77 | ||
| Q3 24 | $0.10 | $-11.61 | ||
| Q2 24 | $0.07 | $-43.48 | ||
| Q1 24 | $0.11 | $-2.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.1M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $219.0M | $23.0M |
| Total Assets | $1.2B | $30.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.1M | — | ||
| Q3 25 | $56.0M | — | ||
| Q2 25 | $59.4M | — | ||
| Q1 25 | $63.5M | — | ||
| Q4 24 | $69.2M | — | ||
| Q3 24 | $45.6M | — | ||
| Q2 24 | $65.1M | — | ||
| Q1 24 | $64.6M | — |
| Q4 25 | $219.0M | $23.0M | ||
| Q3 25 | $230.0M | $24.2M | ||
| Q2 25 | $231.4M | $25.7M | ||
| Q1 25 | $231.9M | $22.7M | ||
| Q4 24 | $237.8M | $23.5M | ||
| Q3 24 | $243.0M | $25.0M | ||
| Q2 24 | $242.1M | $23.5M | ||
| Q1 24 | $242.8M | $24.8M |
| Q4 25 | $1.2B | $30.1M | ||
| Q3 25 | $955.7M | $31.5M | ||
| Q2 25 | $998.4M | $32.0M | ||
| Q1 25 | $1.1B | $29.2M | ||
| Q4 24 | $1.1B | $30.6M | ||
| Q3 24 | $1.3B | $30.1M | ||
| Q2 24 | $1.3B | $29.3M | ||
| Q1 24 | $1.4B | $31.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $10.1M | $-1.6M |
| Free Cash FlowOCF − Capex | — | $-1.6M |
| FCF MarginFCF / Revenue | — | -18.9% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.1M | $-1.6M | ||
| Q3 25 | $1.1M | $-727.8K | ||
| Q2 25 | $3.6M | $-1.3M | ||
| Q1 25 | $4.1M | $-1.7M | ||
| Q4 24 | $27.1M | $-3.4M | ||
| Q3 24 | $6.2M | $-1.4M | ||
| Q2 24 | $5.5M | $-4.6M | ||
| Q1 24 | $9.1M | $-3.2M |
| Q4 25 | — | $-1.6M | ||
| Q3 25 | — | $-735.8K | ||
| Q2 25 | — | $-1.4M | ||
| Q1 25 | — | $-1.7M | ||
| Q4 24 | — | $-3.5M | ||
| Q3 24 | — | $-1.9M | ||
| Q2 24 | — | $-5.6M | ||
| Q1 24 | — | $-3.2M |
| Q4 25 | — | -18.9% | ||
| Q3 25 | — | -7.8% | ||
| Q2 25 | — | -15.2% | ||
| Q1 25 | — | -19.3% | ||
| Q4 24 | — | -36.6% | ||
| Q3 24 | — | -22.2% | ||
| Q2 24 | — | -59.7% | ||
| Q1 24 | — | -43.1% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 6.1% | ||
| Q2 24 | — | 10.5% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | — | — | ||
| Q3 25 | 0.62× | — | ||
| Q2 25 | 0.98× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 5.66× | — | ||
| Q3 24 | 0.99× | — | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | 1.30× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
